Sexual behaviour and risk factors for the acquisition of human papillomavirus infections in young people in Italy: suggestions for future vaccination policies

Donatella Panatto¹*, Daniela Amicizia¹, Cecilia Trucchi¹, Francesca Casabona¹, Piero Luigi Lai¹, Paolo Bonanni², Sara Boccalini², Angela Bechini², Emilia Tiscione², Carla Maria Zotti³, Rosa Cristina Coppola⁴, Giuseppina Masia⁴, Angelo Meloni⁴, Paolo Castiglia⁵, Andrea Piana⁵ and Roberto Gasparini¹

Abstract

Background: Human Papillomavirus (HPV) is the most common sexually transmitted infection. The main risk factors correlated with HPV infection are: early sexual debut, the number of partners, frequency and type of sexual contact and partner's sexual histories. We surveyed sexual habits among young people in order to provide information that might orient decision-makers in adopting HPV multi-cohort vaccination policies.

Methods: We administered a questionnaire to students (14–24 years old) in five Italian cities.

Results: 7298 questionnaires were analyzed (4962 females and 2336 males); 55.3% of females (95% CI 53.9–56.7) and 52.5% of males (95% CI 50.5–54.5) reported regular sexual activity. The mean age at sexual debut was 15.7 ± 1.6 and 15.6 ± 1.6 for females and males, respectively, and the median age was 16 for both sexes. With regard to contraceptive use during the last year, 63.6% of males and 62.8% of females responded affirmatively; 42.6% of males and 42.8% of females used condoms.

Conclusion: The results reveal precocious sexual activity among respondents, with the mean age at first intercourse declining as age decreases. Condom use proved to be scant. Considering lifestyle-related risk factors, males appear to have a higher probability of acquiring HPV infection than females. These data support the importance of promoting multi-cohort HPV vaccination strategies for females up to 25 years of age. It is essential to improve vaccination coverage through different broad-spectrum strategies, including campaigns to increase awareness of sexually transmitted diseases and their prevention.

Keywords: Sexual behaviour, Human papillomavirus, Adolescents, Young people, HPV vaccination, Sexually transmitted diseases (STDs)
Background

Human Papillomavirus (HPV) is one of the most commonly sexually transmitted infections in sexually active adolescents and young people worldwide. HPV is generally spread through sexual contact [1] and direct skin-to-skin contact, the most common route of transmission being through penetrative sex [2].

All sexually active men and women are susceptible to acquiring genital HPV infection. The life-time risk of HPV infection is up to 80%. Most of these infections (up to 90%) are cleared within 2 years (12–24 months) and only a few become persistent [3]. The first HPV infection often occurs soon after the first sexual intercourse (FSI), the cumulative rate of genital HPV infection being approximately 50% over 3 years after the first intercourse [4,5]. The prevalence of HPV infection is highest among young women (18–24 years) soon after the onset of sexual activity, and falls gradually with age until the 4th-5th decade, when a second peak occurs for hormonal changes during perimenopause, followed by another decline [6]. Young subjects are exposed to HPV infection more often because of their sexual behaviour, and young women are more vulnerable than older women because the transformation zone is located on the ectocervix (cervical ectopy) [7].

The likelihood of developing precancerous lesions increases with persistent infections [8]. Persistent infection with an oncogenic type of HPV is a prerequisite to developing cervical cancer [9] and can determine cancer in other anatomical sites, such as the anus, vagina, vulva, oral cavity and oropharynx [10,11].

The most frequent risk factors correlated with the infection and persistence of HPV in the population are the following: initiation of sexual activity at a young age, the number of life-time sexual partners, frequency of sex or other intimate skin-to-skin contact, the sexual histories and behaviours of sexual partners, cigarette smoking, parity, the use of some types of oral contraceptives and alcohol consumption [2].

It is known that, among 150 different HPV types, only about 60 are able to infect the ano-genital area and that vaccination is a useful tool for preventing HPV infection caused by types more frequently involved [12–17]. For some years, two HPV vaccines have been on the market in Europe (EU): a quadrivalent vaccine (Gardasil®), licensed in September 2006, and a bivalent vaccine (Cervarix®), licensed in September 2007. Both vaccines have a prophylactic indication and are able to prevent precancerous lesions (CIN II +) and cancers due to persistent infection with HPV-16 or HPV-18. Furthermore, both vaccines have been shown to elicit cross-protection against other high-risk HPV types [13–17]. Gardasil® also offers protection against genital warts caused by HPV-6 and HPV-11.

As HPV infection is exclusively contracted through sexual activity, it was recommended that adolescent females should be vaccinated against HPV before their sexual debut, as the main target population. Therefore, in March 2008, the Italian Ministry of Health recommended that regional authorities should start a campaign of free HPV vaccination for 12-year-old girls [18]. Since the introduction of HPV vaccination, many studies have been conducted with the aim of helping decision-makers choose the best vaccination policy [19–24].

Another important issue concerns the coverage rate, since only by achieving high coverage can circulation of the virus be rapidly reduced, thereby exerting a greater impact on diseases related to HPV genotypes. Indeed, in its HPV immunization plan, the Italian Ministry of Health has set the goal of achieving 95% coverage within 5 years of initiating the vaccination program in 12-year-old girls [18].

As many studies [2,25,26] of HPV prevalence and incidence indicate that the most consistent predictor of infection is sexual activity, particularly age on first intercourse and the number of sexual partners, we carried out a study of sexual habits among young people in Italy in order to provide information that might orient decision-makers in the choice of a multi-cohort vaccination policy; indeed, knowing the age of onset of sexual activity is essential to guiding Regional Health Authority recommendations regarding the optimal age for prophylactic HPV vaccination. The study did not envisage collecting data on vaccination acceptance.

Methods

The study was approved by Ethic Committee of the Genoa Local Healthcare Unit, Italy (Azienda Sanitaria Locale 3 Genovese).

The study was carried out from May 2008 to May 2011.

Questionnaire

We administered an ad hoc written questionnaire in order to survey the sexual behaviour and risk factors for HPv infections among young students (14–24 years old) in five Italian cities: Genoa, Florence, Turin, Cagliari and Sassari. The questionnaire comprised 20 questions covering the following specific items: demographics, level of education, sexual activity (penetrative genital-genital sex), age at first sexual intercourse, and sexual behaviour in terms of the number of sexual partners and contraceptive use (Additional file 1). The definition of regular sexual activity was to have sexual intercourse two or more times a month [27].

It took about 20 minutes to answer the self-administered questionnaire. In order to encourage openness and honesty in the answers, confidentiality and
At the age of 15 years. This group also included subjects who had 2 partners but had been involved in sexual activity before the age of 15 years. No statistically significant differences were found on considering gender.

The study considered only subjects who declared regular sexual activity after their sexual debut. However, 21 females and 15 males who declared having had a sexual debut reported irregular sexual activity. These volunteers have been included in the group of subjects “NO regular sexual activity” (Table 1).
Table 1 shows regular sexual activity and age at sexual debut by age-group and gender. It also reports the sexually active subjects who stated regular sexual activity prior to their 15th birthday. The percentage of subjects in each age-group who were sexually active before their 15th birthday was calculated in order to better assess the changes in sexual habits among the young.

With regard to regular sexual activity, a significant (p < 0.001) increasing trend in proportions by age was observed in both sexes.

Among females, the mean age at sexual debut was 15.7 ± 1.6 and the median age was 16 (25th and 75th percentiles = 15-17). Among males, the mean age at sexual debut was 15.6 ± 1.6 and the median age was 16 (25th and 75th percentiles = 15-17).

Comparison of the mean ages at sexual debut among the age-groups of respondents of the same sex was carried out by means of analysis of variance (ANOVA). This revealed a highly significant difference (p < 0.001), indicating that, among the subjects who declared sexual activity, younger subjects debuted earlier than their older counterparts. Most females had their first sexual intercourse with a partner 2.4 years older, while males first had intercourse with a partner 0.5 years older (data not shown).

Table 2 shows the characteristics of sexual behaviour by gender and age-group among sexually active subjects. The number of lifetime sexual partners increases with age in both sexes, and males report more multiple partnerships than females. No difference was found in the number of partners prior to the respondent’s 15th birthday, nor in the number of sexual partners in the last year among the different age-groups.

Figure 1 reports the numbers and percentages of males and females, broken down according to the risk of acquiring HPV infection. Among males, 434 (38.2% 95%CI 35.8-40.5), 232 (20.4% 95%CI 18.4-22.3) and 470 (41.4% 95%CI 39.9-43.8) subjects fell into the low-risk, medium-risk and high-risk groups, respectively. Among females, 1479 (55.0% 95%CI 53.1-56.9), 524 (19.5% 95%CI 18.0-20.9)
and 686 (25.5% 95%CI 23.8-27.1) subjects fell into the low-risk, medium-risk and high-risk groups, respectively. Table 3 shows the percentage of subjects who used a contraceptive method during their sexual debut by gender and age-group. Overall, the use of a contraceptive method at sexual debut was reported by 62.2% (95% CI 59.5-64.9) of males; 58.9% (95% CI 56.1-61.6) indicated using a condom. Among females, 70.3% (95% CI 67.4-73.4) used a contraceptive method at sexual debut.

| Age-group (years) | FEMALES | MALES |
|-------------------|---------|-------|
| 14-16             | 668 (NR* = 21) | 1293 (NR* = 23) |
| 15-19             | 732 (NR* = 9) | 330 (NR* = 7) |
| 20-24             | 575 (NR* = 19) | 286 (NR* = 10) |

| Gender | Lifetime sexual partners (number) | * NR = non-responders. |
|--------|-----------------------------------|-------------------------|
| MALES  | N° | Mean age | SD | Range |
| FEMALES| N° | Median | 25th-75th P | Range |
| MALES  | N° | Median | 25th-75th P | Range |
| FEMALES| N° | Median | 25th-75th P | Range |
| MALES  | N° | Median | 25th-75th P | Range |
| FEMALES| N° | Median | 25th-75th P | Range |

Table 2 Characteristics of sexual behaviour by gender and age-group among respondents who declared sexual activity

![Figure 1 Number of males and females in the various HPV risk-groups.](http://www.biomedcentral.com/1471-2458/12/623)
68.6-72.0) reported using a contraceptive method at sexual debut; 67.2% (95% CI 65.9-69.3) specified using a condom. Moreover, a significant (females: $p < 0.001$; males: $p < 0.05$) increasing trend in proportions of the use of contraceptive methods by age was observed in both sexes.

With regard to the use of contraceptive methods during the last year, 63.6% (95% CI 60.7-66.5) of males responded affirmatively, and 42.6% (95% CI 39.5-45.6) reported using a condom. Among females, 62.8% (95% CI 60.9-64.7) responded affirmatively: 42.8% (95% CI 40.8-44.7) reported using a condom and 21.2% (95% CI 19.6-22.8) oral contraception.

With regard to the use of a contraceptive method during the last year by gender and age-group, an increasing trend ($p < 0.05$) was observed by age for males (Table 3).

Discussion

This paper reports the results of a study of self-reported sexual behaviour in adolescents and young people aged 14–24 years in Italy.

More than two thirds of the students involved in this study were females, who constitute the target population of HPV vaccination. The results yielded by this sample therefore enabled the suitability of the current vaccination strategies in Italy to be evaluated indirectly, in that sexual activity is the most consistent predictor of the probability of acquiring HPV infection.

Exposure to HPV infection is determined by risks factors such as an early sexual debut, a high number of lifetime sexual partners, a high number of recent or current sexual partners and the sexual histories and behaviours of sexual partners [2,25]. Condom use has a protective effect, although its effectiveness in reducing HPV acquisition has not been completely clarified [32,33].

The results of our study highlight the early start of sexual activity among young students in Italy, with a mean age at first intercourse on comparing the various age-groups of the subjects (Table 2);
indeed, in the 14–16 age-group, 47.5% of the sexually active females and 60.2% of the sexually active males reported having their first sexual intercourse before their 15th birthday, and a third of the interviewees aged 14–16 years old declared that they already indulged in regular sexual activity.

Most of the females stated that their sexual debut was with a partner 2.4 years older, while the males reported their first intercourse with a partner of the same age. As the sexual behaviour of the partner, particularly the number of previous sexual partners, is a risk factor for the transmission of mucosal HPV infection, having an older partner increases the probability of acquiring the virus. Consequently, females could have a higher risk than males at sexual debut.

The number lifetime sexual partner increases with age, and males report more multiple partnerships than females.

On the basis of age at sexual debut and the number of lifetime sexual partners, the respondents were grouped into different risk-group. Considering lifestyle-related risk factors, males appear to have a higher probability of acquiring HPV infection than females. Indeed, more males fell into the high-risk group (41.4%) than the low- (38.2%) or medium-risk groups (20.4%), while most females were in the low-risk group (55.0%). The exact probability of transmission through sexual contact or partnership is not precisely known. Barnabas et al. estimated a value of transmission probability using a mathematical modelling analysis. They considered that the transmission probability could varied between 0 to 1, and they found that the probability of transmission was approximately 0.4 for annual partner change rate [28]. Burchell et al. report a partnership transmission probability of 0.20; they observe little difference in the rate of male-to-female (3.5 transmissions per 100 person-months) versus female-to-male transmission (4.0 transmissions per 100 person-months) [35]. Other studies have found higher rates of female-to-male than male-to-female transmission [36–38].

Our data indicate a low use of condoms. With regard to regular condom use during the last year, no difference between the genders emerged. In the female group, however, we noted statistically significant differences (p < 0.05) between age-groups. The percentage of females who regularly use condoms was seen to decline as age increased, in particular in the 20–24 age-group. This could be explained by the fact that older females reported more stable and durable relationships and a greater use of the pill. We surmise, also on the basis of literature data [39,40], that many young people use condoms to prevent unwanted pregnancies, but that they have scant knowledge or perception of the risk of sexually transmitted infections. In the male group, the percentage of students who regularly use condoms increased with increasing age.

Direct comparison of our results with data from other studies conducted in Italy and other European countries is complicated by the different methodologies used and the different populations monitored. A study published in 2006 reported data on sexual behaviour in 59 countries worldwide during the period 1996–2006. The authors found median ages at sexual debut of 17.5 and 18.5 years among young men and women, respectively, in Italy. The difference between these findings and those of our study can be attributed to the cohorts of the subjects interviewed; our students were born between 1984 and 1996, while those of Wellings' study were born between 1965 and 1969 [41]. This confirms a lifestyle change in recent years. In a survey conducted in 2006–2007 in 7 European countries, Crochard et al. reported a median age at sexual debut of 16 and 17 for males and females, respectively, in Italy [25]. Our research group carried out an investigational study on sexual behaviours among adolescents in a Region of Northern Italy from 2006 to 2007, and found similar results [42].

Conclusions
These data confirm the importance of promoting multi-cohort HPV vaccination strategies for young females. The strategy of free vaccination for females up to 25 years of age in Italy appears advantageous. This approach would rapidly reduce circulation of the virus and, consequently, have a greater impact on diseases related to HPV genotypes at high oncogenic risk.

Furthermore, it is essential to make every effort to improve the coverage of HPV vaccination. Indeed, data on coverage in Italy (updated as of 30th June 2011) revealed a coverage rate of 65% for the primary target of vaccination (12-year-old girls); since the beginning of the immunization program, no improvement has yet been observed [43]. To this end, it is necessary to implement a range of broadband strategies, including communication campaigns to increase awareness of sexually transmitted infections and their prevention. Teenagers’ sexual behaviours have both short-term and long-term consequences, and interventions that focus on this target population may be the most effective in helping to promote overall health among young adults.

Information campaigns can only be successful if they reach their target populations. In the present case, as our target population is that of young people, we should exploit the means of communication which they themselves use, such as social networks (facebook, twitter) and websites dedicated to the young (information online). To achieve high coverage rates of anti-HPV vaccination, these channels of communication have been utilised in the United Kingdom, where very good results have been obtained within a short time [44].
Finally, it is very important that everybody understand that safe and efficacious vaccines for the prevention of cervical cancer are available and provide important individual and public benefits.

Additional file

Additional file 1: Questionnaire.

Abbreviations
HPV: Human papillomavirus; FSI: First sexual intercourse; NR: Non-responders; CI: Confidence interval; STDs: Sexually Transmitted Diseases.

Competing interest
The authors declare that they have no competing interests.

Authors’ contributions
RG supervised the research; RG and DP designed the study and coordinated the Genova unit research; PPL optimized the informatics database; RG, DP, PLL, PC, AP performed the statistical analyses and evaluated the results; DP and DA wrote the manuscript; PB, RCC, PC, CMZ coordinated the data collection in Florence, Cagliari, Sassari and Turin and performed the final local quality control; CT, FC, SB, AB, ET, GM, AM, AP collected data and made the first local quality control; All Authors revised the manuscript and gave their contribution to improve the paper; All authors read and approved the final manuscript.

Acknowledgments
The authors thank Dr. Patrick Bernard for revising the manuscript.

Author details
1Department of Health Sciences, University of Genoa, Via Pastore, 1 16132 Genova, Italy. 2Department of Public Health, University of Florence, Florence, Italy. 3Department of Public Health and Microbiology, University of Turin, Turin, Italy. 4Department of Biomedical Sciences, University of Sassari, Sassari, Italy. 5Department of Public Health and Microbiology, University of Turin, Turin, Italy.

Received: 23 February 2012 Accepted: 27 July 2012

Published: 7 August 2012

References
1. Burchell AN, Winer RL, de Sanjose S: Chapter 6: Epidemiology and transmission dynamics of genital HPV infection. Vaccine 2006, 24(Suppl 3):S2–S61.
2. Wijhuzen NJ, Snijders PJ, Reiss P, Meijer CJ, van de Wijger JH: Factors affecting transmission of mucosal human papillomavirus. Lancet Infect Dis 2010, 10:862–874.
3. Rodriguez AC, Schiffman M, Herrero R, Wacholder S, Hildesheim A, Castle PE, Solomon D, Burk R: Proyecto Epidemiologico Guanacaste Group: Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst 2008, 100:513–517.
4. Lehtinen M, Paavonen J: Vaccine against sexually transmitted human papillomavirus infection – the beginning of the end for cervical cancer. CME: Journal of Gynecologic Oncology 2004, 20:210–213.
5. Winer RL, Lee SK, Hughes JP, Adam DE, Proveaux T, Zhao X, Halsey N, Giuliano AR: Human papillomavirus vaccination: what is the best choice? A comparison of 16 strategies by means of a decisional model. Epidemiol Rev 2009, 31:794–802.
6. Lefèvre E, Hens N, De Smet F, Van Damme P: Dynamics of HPV vaccination initiation in Flanders (Belgium) 2007–2009: a Cox regression model. BMC Public Health 2011, 11:470.
7. Dorleans F, Giambi C, Dematte L, Cotter S, Stefanoff P, Mereckiene J, D’Flanagan D, Lopalco PL, D’Amorfo F, Levy-Bruhl D: VENICE 2 project gatekeepers group: the current state of introduction of human papillomavirus vaccination into national immunisation schedules in Europe: first results of the VENICE 2010 survey. Euro Surveill 2010, 15 pii:19730.
8. Adams M, Jasani B, Fidler A: Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening. Vaccine 2007, 25:3007–3013.
9. Castellsague X, Schneider A, Kaufmann AM, Bosch FX: HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives. Gynecol Oncol 2009, 115(Suppl 3):S15–23.
10. Gillison ML: Oropharyngeal cancer: a potential consequence of concomitant HPV and HIV infection. Curr Opin Oncol 2009, 21:439–444.
11. Trotter H, Burchell AN: Epidemiology of mucosal human papillomavirus infection and associated diseases. Public Health Genomics 2009, 12:291–307.
12. Chen Z, Schiffman M, Herrero R, Desale R, Anastasi K, Segondy M, Sahasrabuddhe VV, Gavrill PE, Hsing AW, Burk RD: Evolution and taxonomic classification of human papillomavirus 16 (HPV16)-related variant genomes: HPV31, HPV33, HPV58, and HPV67. PLoS One 2011, 6:e21813.
13. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisarann U, Limton G, Garland S, Sarewski A, Romanovski B, Aoki FY, Schwarz TF, Poppe WA, Boschi FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtimink M, Dubin G: HPV PATRICIA Study Group: Efficacy of human papillomavirus (HPV)-16/18, A504-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2010, 376:1045–1054.
14. Quadrivalent HPV Vaccine Phase III/IV Investigators, Huh WK: Impact of quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle vaccine on the incidence of abnormal pap tests and cervical procedures. [Abstract], Gynecol Oncol 2008, 108(Suppl 11):S10.
15. Brown DR, Kajer SK, Sigurdsson K, Iversen DE, Hernandez-Avil A, Wheeler CM, Perez G, Koutzky LA, Tay EH, Garcia P, Ault KA; Garland SA, Leodoller S, Olsson SE, Tang GM, Fennis DG, Paavonen J, Sieben M, Boschi FX, Dillner J, Joura EA, Kuman RJ, Majewski S, Munoz N, Myers ER, villa LL, Taddess FI, Roberts C, Tadesse A, Bryan J, Lupinciuc LC, Giacoletti KE, Sings HG, James M, Hesley TM, Barr E: The impact of quadrivalent human papillomavirus (HPV) types 6, 11, 16, and 18 L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16–26 years. J Infect Dis 2009, 199:396–405.
16. Skinner R, Apter D, Chow SN, Wheeler C, Dubin G: Cross-protection efficacy of Cervarix™ against oncogenic HPV types beyond HPV-16/18. Malmö, Sweden, 2009: Abstract n° O-29.01 Presented at the 25th International Papillomavirus Conference.
17. Garfand SM, Steben M, Singh HJ, James M, Lu S, Ralkar R, Barr E, Haupt RM, Joura EA: Natural History of Genital Warts: Analysis of the Placebo Arm of 2 Randomized Phase III Trials of a Quadrivalent Human Papillomavirus Vaccine. J Infect Dis 2009, 199:801–814.
18. Intesa tra il governo, le Regioni e le Provincie autonome concerne Strategie per l’offerta attiva del vaccino contro l’infezione da HPV in Italia del 20 dicembre 2007. http://www.statoregioni.it/Documenti/DOC_016696_264%20crp.pdf.
19. Gasparini R, Amicizia D, Manfredi P, Ansaldo F, Lucioni C, Gallelli G, Panatto D: Human papillomavirus vaccination: what is the best choice? A comparison of 16 strategies by means of a decisional model. Epidemiol Rev 2009, 31:794–802.
20. Dorleans F, Giambi C, Dematte L, Cotter S, Stefanoff P, Mereckiene J, D’Flanagan D, Lopalco PL, D’Amorfo F, levy-Bruhl D, VENICE 2 project gatekeepers group: the current state of introduction of human papillomavirus vaccination into national immunisation schedules in Europe: first results of the VENICE 2010 survey. Euro Surveill 2010, 15 pii:19730.
21. World Health Organization: Preparing for the Introduction of HPV Vaccine in the WKO European Region. Strategy paper. http://www.euro.who.int/__data/assets/pdf_file/0007/98746/E91432.pdf.
22. Shenfeld Gorin SN, Glenn BA, Perkins RB: The human papillomavirus (HPV) vaccine and cervical cancer: uptake and next steps. Adv Ther 2011, 28:615–639. doi:10.1007/s12325-011-0045-x.
23. Vadsaprampl ST, Kahn JA, Salomon D, Lee JM, Quinn GP, Roetzheim R, Kruder K, Malo TL, Proveaux T, Zhao X, Halsey N, Giuliano AR: Missed
clinical opportunities: Provider recommendations for HPV vaccination for
11–12 year old girls are limited. Vaccine 2011, 29:634–8641.
25. Crochard A, Luys D, di Nicola S, Goncalves MA: Self-reported sexual debut
and behavior in young adults aged 18–24 years in seven European
countries: implications for HPV vaccination programs. Gynecol Oncol
2009, 115:57–14.
26. Moschicki AB: HPV infections in adolescents. Dis Markers 2007, 23:229–234.
27. Lindau ST, Gavrilova N: Sex, health, and years of sexually active life gained
due to good health: evidence from two US population based cross
sectional surveys of ageing. BMJ 2010, 340:c810. doi:10.1136/bmjc810.
28. Barnabas RV, Laukkanen P, Koskela P, Kontula O, Lehimen M, Garnett GP:
Epidemiology of HPV 16 and cervical cancer in Finland and the potential
impact of vaccination: mathematical modeling analyses. PLoS Med 2006,
3:e24–e62.
29. Technical University of Denmark: Web pages that perform statistical
calculations. http://statpages.org.
30. Open Source Epidemiologic Statistics for Public Health. http://www.openepi.com.
31. R Development Care Team: R: A language and environment for statistical
computing. Vienna, Austria: R Foundation for Statistical computing; 2011.
ISBN 3-900051-07-0. URL [http://www.R-project.org/].
32. Winer RL, Hughes JP, Feng Q, O’Reilly S, Kiviats NB, Holmes KK, Koutsky LA:
Condom use and the risk of genital human papillomavirus infection in
young women. NEJM 2006, 354:2646–2654.
33. Nielsen CM, Harris RB, Nyitray AG, Dunne EF, Stone KM, Giuliano AR:
Consistent condom use is associated with lower prevalence of human
papillomavirus infection in men. J Infect Dis 2010, 202:445–451.
34. Madkour AS, Farhat T, Halpern CT, Godeau E, Gabhainn SN: Early
adolescent sexual initiation as a problem behavior: a comparative study
of five Nations. J Adolesc Health 2010, 47:389–398.
35. Burchell AN, Coutlée F, Teller P, Lankey J, Franco EL: Genital Transmission
of Human papillomavirus in recently formed heterosexual couples. JID
2011, 204:1723–1729.
36. Hernandez B, Willens L, Zhu X, Thompson P, McDuffie K, Shvetsov YB,
Kamimoto LE, Killeen J, Ning L, Goodman MT: Trasmission of human
papillomavirus in heterosexual couples. Emerg Infect Dis 2008, 14:888–894.
37. Widdoe L, Ma Y, Farhat S, Farhat S, Ma Y, Leonard AC, Moscicki AB:
Concordance and transmission on human papillomavirus. In International
Papillomavirus Conference. Montreal Canada; 2010. http://hpv2010.org.
38. Mbulawa ZZA, Marais DJ, Coetzee D, Williamson AL: HPV transmission in
heterosexually active couples over 12 months. In International
Papillomavirus Conference. Montreal Canada; 2010. http://hpv2010.org.
39. Novak DP, Karlsson RB: Gender differed factors affecting male condom
use. A population-based study of 18-year-old Swedish adolescents. Int J
Adolesc Med Health 2005, 17:4:379–00.
40. Leval A, Sundstrom K, Ploner A, Dahlstrom LA, Wildmark C, Saren P:
Assessing perceived risk and STI prevention behavior: a national
population-based study with special reference to HPV. PloS One 2011,
6(5):e20624.
41. Wellings K, Collumbien M, Slaymaker E, Singh S, Hodges Z, Patel D, Bajos N:
Sexual behaviour in context: a global perspective. Lancet 2006,
368:1706–1728.
42. Panatto D, Amicizia D, Lugarini J, Sasso T, Sormani MP, Badolati G, Gasparini R:
Sexual behaviour in Ligurian (Northern Italy) adolescents and young
people: suggestions for HPV vaccination policies. Vaccine 2009,
27:636–A10.
43. Stato di avanzamento della campagna vaccinale per l’HPV: dati di copertura
vaccinale al 30/06/2011. www.epicentro.iss.it/problemi/hpv/pdf/HPV-30-06-
2011.pdf.
44. National Services Scotland: Child Health. http://www.isdscotlandarchive.scot.
www.isdscotlandarchive.scot. html.

Submit your next manuscript to BioMed Central and take full advantage of:

• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit

doi:10.1186/1471-2458-12-623
Cite this article as: Panatto et al.: Sexual behaviour and risk factors for
the acquisition of human papillomavirus infections in young people in
Italy: suggestions for future vaccination policies. BMC Public Health 2012
12:623.